DERMCARE IMMUNOTHERAPY Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dermcare immunotherapy

dermcare-vet pty. ltd. - allergenic mixture; allergenic extract - parenteral liquid/solution/suspension - allergenic mixture ungrouped active 20000.0 pnu; allergenic extract ungrouped active 2000.0 pnu - immunotherapy - dog | bitch | castrate | puppy - allergic dermatitis | atopy

INGESTANTS EXTRACTS Israel - English - Ministry of Health

ingestants extracts

trupharm marketing 1985 ltd. - food extract - solution for injection - food extract - allergen extracts - skin testing and immunotherapy.

Oralair 100IR & 300IR sublingual tablets Ireland - English - HPRA (Health Products Regulatory Authority)

oralair 100ir & 300ir sublingual tablets

stallergenes - grass pollen allergen extract - sublingual tablet - 100/300 index of reactivity - allergen extracts; grass pollen

Oralair 300 IR sublingual tablets Ireland - English - HPRA (Health Products Regulatory Authority)

oralair 300 ir sublingual tablets

stallergenes - grass pollen allergen extract - sublingual tablet - 300 index of reactivity - allergen extracts; grass pollen

5 GRASS MIX- phleum pratense pollen, dactylis glomerata pollen, poa pratensis pollen, agrostis gigantea pollen, anthoxanthum odo United States - English - NLM (National Library of Medicine)

5 grass mix- phleum pratense pollen, dactylis glomerata pollen, poa pratensis pollen, agrostis gigantea pollen, anthoxanthum odo

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 1000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

CENTER-AL - ACACIA LONGIFOLIA POLLEN- acacia longifolia pollen injection, suspension
CENTER-AL - ALNUS INCANA SSP. RUGOSA POLLE United States - English - NLM (National Library of Medicine)

center-al - acacia longifolia pollen- acacia longifolia pollen injection, suspension center-al - alnus incana ssp. rugosa polle

alk-abello, inc. - acacia longifolia pollen (unii: 24so2j296o) (acacia longifolia pollen - unii:24so2j296o) - acacia longifolia pollen 10000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

CENTER-AL - CHENOPODIUM ALBUM POLLEN- chenopodium album pollen injection, suspension
CENTER-AL - ACER SACCHARUM POLLEN- acer sa United States - English - NLM (National Library of Medicine)

center-al - chenopodium album pollen- chenopodium album pollen injection, suspension center-al - acer saccharum pollen- acer sa

alk-abello, inc. - chenopodium album pollen (unii: 098lkx5ncn) (chenopodium album pollen - unii:098lkx5ncn) - chenopodium album pollen 10000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

CENTER-AL - POPULUS DELTOIDES SSP. MONILIFERA POLLEN- populus deltoides subsp. monilifera pollen injection, suspension
CENTER-A United States - English - NLM (National Library of Medicine)

center-al - populus deltoides ssp. monilifera pollen- populus deltoides subsp. monilifera pollen injection, suspension center-a

alk-abello, inc. - populus deltoides subsp. monilifera pollen (unii: 5928lj1441) (populus deltoides subsp. monilifera pollen - unii:5928lj1441) - populus deltoides subsp. monilifera pollen 10000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

CENTER-AL - BROMUS INERMIS POLLEN- bromus inermis pollen injection, suspension United States - English - NLM (National Library of Medicine)

center-al - bromus inermis pollen- bromus inermis pollen injection, suspension

alk-abello, inc. - bromus inermis pollen (unii: 766qt72bk6) (bromus inermis pollen - unii:766qt72bk6) - bromus inermis pollen 10000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

Alustal Australia - English - Department of Health (Therapeutic Goods Administration)

alustal

stallergenes australia pty ltd - plantago lanceolata; triticum aestivum; olea europaea; european house dust mite extract; american house dust mite extract; dermatophagoides pteronyssinus body extract; dermatophagoides farinae body extract; lolium perenne; phleum pratense; dactylis glomerata; anthoxanthum odoratum; poa pratensis; cynodon dactylon; mannitol; arrhenatherum elatius; holcus lanatus; avena fatua; bromus inermis; agrostis tenuis; festuca elatior; holcus latanus; cynodon dactylon pollen extract; dermatophagoides farinae body extra -